Men initially diagnosed with de novo metastatic prostate cancer are living longer

A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …

Contemporary rates of overall and prostate cancer-specific mortality in Norway

A newly published study in the journal Urology (“the Gold journal”) has reported data on risk of death from prostate cancer and other causes among > 3,000 contemporary patients diagnosed with non-metastatic prostate cancer in 2004-2005. … READ MORE …

Should every prostate cancer patient be on a statin?

A recent article in the Journal of Clinical Oncology, together with an associated editorial, have addressed the issue of whether evidence is now sufficient to argue that all men with prostate cancer should be treated with a statin. … READ MORE …

This may put the cat among the pigeons!

A large, newly published, observational study has suggested that comorbidity affects other-cause mortality but not prostate cancer-specific mortality after accounting for patient and tumor characteristics and treatment type. … READ MORE …

The prostate cancer “screening” controversy … an update

Yesterday we mentioned a new paper on PSA screening by Tsodikov et al. in the Annals of Internal Medicine. We have now had the chance to read the full text of that paper, as well as the associated editorial by Vickers in the same issue of the journal. … READ MORE …

More on statins and the management of prostate cancer

A recent data analysis for the Danish national health registry systems has once again provided confirmation of a link between statin use and risk of prostate cancer-specific mortality. … READ MORE …

Physical activity and prostate cancer-specific survival times

Yet another study has confirmed the benefits of regular exercise in the prevention or delay of prostate cancer-specific mortality among men with non-metastatic prostate cancer. … READ MORE …